A Randomized Study of BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X Syndrome
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This is a 2-part study, with each part having a unique set of objectives for male adolescents
aged 12 to < 18 years with fragile X syndrome (FXS). Part 1 is an open-label, single-dose,
pharmacokinetics (PK) assessment of BPN14770 25 mg and 50 mg, while Part 2 is double-blind
(DB) and randomized between three treatment groups (High Dose, Low Dose, and Placebo)